A Survival God for the Age of Abundance,” Peter H. Diamandis and Steven Kotler explore what it means to be human in a world ...
From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating ...
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...
On Tuesday, AgiBot, a Shanghai-based embodied AI company, broadcast live from the intelligent manufacturing center of Longcheer, a leading smart device designer and manufacturer, in Nanchang, capital ...
Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in ...
Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies ...
Will Spider-Man cross a moral line in Amazing Spider-Man #27? DEATH SPIRAL concludes as Torment pushes our hero to the ...
Researchers showed that an experimental therapy indirectly converted suppressive immune cells into tumor-fighting cells. This ...
A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results